nintedanib, Nintedanib, nintedanib clinical trials

An open-label trial of the long-term safety and tolerability of nintedanib per os, on top of standard of care, over at least 3 years, in children and adolescents with clinically significant fibrosing Interstitial Lung Disease (InPedILD®-ON)

This study looks at a medicine called nintedanib for children and young people with a serious lung condition called Interstitial Lung Disease (ILD). It aims to check its long-term safety over at least three years, alongside their usual care, to see how well it's tolerated.